Castleview Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.22M | Buy |
69,470
+1,574
| +2% | +$72.9K | 2.07% | 7 |
|
|
2025
Q1 | $4.14M | Buy |
67,896
+12,703
| +23% | +$775K | 2.8% | 3 |
|
|
2024
Q4 | $3.13M | Buy |
55,193
+5,752
| +12% | +$327K | 1.69% | 5 |
|
|
2024
Q3 | $2.56M | Buy |
49,441
+43,730
| +766% | +$2.26M | 1.48% | 11 |
|
|
2024
Q2 | $237K | Buy |
5,711
+2,030
| +55% | +$84.3K | 0.13% | 153 |
|
|
2024
Q1 | $200K | Buy |
3,681
+1,199
| +48% | +$65K | 0.11% | 178 |
|
|
2023
Q4 | $127K | Buy |
2,482
+422
| +20% | +$21.7K | 0.09% | 181 |
|
|
2023
Q3 | $120K | Sell |
2,060
-60
| -3% | -$3.48K | 0.11% | 156 |
|
|
2023
Q2 | $136K | Sell |
2,120
-1,395
| -40% | -$89.2K | 0.12% | 149 |
|
|
2023
Q1 | $244K | Buy |
3,515
+130
| +4% | +$9.01K | 0.22% | 110 |
|
|
2022
Q4 | $244K | Buy |
3,385
+531
| +19% | +$38.2K | 0.24% | 100 |
|
|
2022
Q3 | $203K | Buy |
2,854
+2,850
| +71,250% | +$203K | 0.19% | 113 |
|
|
2022
Q2 | $1.94K | Sell |
4
-3,273
| -100% | -$1.59M | ﹤0.01% | 634 |
|
|
2022
Q1 | $239K | Sell |
3,277
-250,861
| -99% | -$18.3M | 0.15% | 139 |
|
|
2021
Q4 | $4.08K | Buy |
+254,138
| New | +$4.08K | 0.03% | 186 |
|
|
2021
Q2 | $178K | Buy |
+2,666
| New | +$178K | 0.08% | 222 |
|
|
2018
Q1 | $363K | Buy |
+5,745
| New | +$363K | 0.3% | 79 |
|